Ensysce Biosciences, Inc.
NASDAQENSC heads into its May 20 earnings event carrying the most aggressive short-side lending profile it has seen all year — a violent, week-long repricing that leaves the stock at $0.28 and the borrow market in a state of near-crisis. The positioning story for Ensysce Biosciences is almost entirely about what happened in the lending market this week. Short interest was running below…
ENSC cost to borrow surges to 235% — up 210% over the past week amid a short squeeze in the micro-cap biotech name.
Short interest % of float, cost to borrow, utilization, and put/call ratio for ENSC are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 16 May 2026
ENSC heads into its May 20 earnings event carrying the most aggressive short-side lending profile it has seen all year — a violent, week-long repricing that leaves the stock at $0.28 and the borrow market in a state of…
ENSC arrives at its May 13 earnings report in an unusual position: the stock is tiny, the short interest is negligible, yet borrowing its shares commands a rate that would embarrass many heavily contested names. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ENSC — free to start on ORTEX.
Sign up for free →Open ENSC on ORTEX